Search
Now showing items 1-3 of 3
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2018)
Introduction Roux-en-Y gastric bypass (GBP) is associated with changes in cardiometabolic risk factors and bioavailability of drugs, but whether these changes are induced by calorie restriction, the weight loss or surgery ...
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2021)
It remains uncertain whether pharmacokinetic changes following Roux-en-Y gastric bypass (RYGB) can be attributed to surgery-induced gastrointestinal alterations per se and/or the subsequent weight loss. The aim was to ...
(Journal article / Tidsskriftartikkel / PublishedVersion; Peer reviewed, 2020)
Obesity is associated with comorbidities of which pharmacological treatment is needed. Physiological changes associated with obesity may influence the pharmacokinetics of drugs, but the effect of body weight on drug ...